| Seth Garrett, MD | |
|
701 Leighton Ave, Anniston, AL 36207-5745 | |
| (256) 231-1231 | |
| (256) 231-1232 |
| Full Name | Seth Garrett |
|---|---|
| Gender | Male |
| Speciality | Physical Medicine And Rehabilitation |
| Experience | 8 Years |
| Location | 701 Leighton Ave, Anniston, Alabama |
| Accepts Medicare Assignments | May be. He may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1396290946 | NPI | - | NPPES |
| MD.38439 | Other | AL | LICENSE |
| 81258 | Other | GA | LICENSE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 38439 (Alabama) | Primary |
| 207LP2900X | Anesthesiology - Pain Medicine | 38439 (Alabama) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Northeast Alabama Regional Medical Center | Anniston, AL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Pm Healthcare, Llc | 9133496862 | 4 |
News Archive
Cook Medical has submitted its Pre-Market Approval (PMA) application to the U.S. Food and Drug Administration (FDA) for the company's unique polymer-free Zilver® PTX® Drug-Eluting Peripheral Stent. Intended for use in patients with peripheral arterial disease (PAD) in the superficial femoral artery (SFA), Zilver PTX is a self-expanding, highly durable nitinol stent that uses a proprietary, polymer-free technology to deliver a locally therapeutic dose of paclitaxel, an antiproliferative drug, to the target lesion.
The incidence of esophageal adenocarcinoma has increased 8-fold over the past 50 years. This is one of the deadliest cancers, with a five-year survival rate of only 20 percent. However, the survival rate more than doubles if the cancer is identified early.
An international Yale-led research team has shown that a risk profile based on 52 genes accurately predicts survival for patients with a severe lung disease. If confirmed in further studies, the finding could transform the way patients are treated for the condition, which is on the rise in older adults.
The nation's emergency physicians are issuing a strong warning to parents about the dangers of prescription drug abuse, which are now the second most abused drugs, after marijuana. Nearly three-quarters of a million people (741,425) needed emergency care in 2006 because of prescription drug abuse.
› Verified 4 days ago
| Entity Name | Alabama Orthopedic Spine & Sports Medicine Associates P C |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1659344984 PECOS PAC ID: 5395643068 Enrollment ID: O20031219000647 |
News Archive
Cook Medical has submitted its Pre-Market Approval (PMA) application to the U.S. Food and Drug Administration (FDA) for the company's unique polymer-free Zilver® PTX® Drug-Eluting Peripheral Stent. Intended for use in patients with peripheral arterial disease (PAD) in the superficial femoral artery (SFA), Zilver PTX is a self-expanding, highly durable nitinol stent that uses a proprietary, polymer-free technology to deliver a locally therapeutic dose of paclitaxel, an antiproliferative drug, to the target lesion.
The incidence of esophageal adenocarcinoma has increased 8-fold over the past 50 years. This is one of the deadliest cancers, with a five-year survival rate of only 20 percent. However, the survival rate more than doubles if the cancer is identified early.
An international Yale-led research team has shown that a risk profile based on 52 genes accurately predicts survival for patients with a severe lung disease. If confirmed in further studies, the finding could transform the way patients are treated for the condition, which is on the rise in older adults.
The nation's emergency physicians are issuing a strong warning to parents about the dangers of prescription drug abuse, which are now the second most abused drugs, after marijuana. Nearly three-quarters of a million people (741,425) needed emergency care in 2006 because of prescription drug abuse.
› Verified 4 days ago
| Entity Name | Crh Umc Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922349083 PECOS PAC ID: 0244478238 Enrollment ID: O20130604000043 |
News Archive
Cook Medical has submitted its Pre-Market Approval (PMA) application to the U.S. Food and Drug Administration (FDA) for the company's unique polymer-free Zilver® PTX® Drug-Eluting Peripheral Stent. Intended for use in patients with peripheral arterial disease (PAD) in the superficial femoral artery (SFA), Zilver PTX is a self-expanding, highly durable nitinol stent that uses a proprietary, polymer-free technology to deliver a locally therapeutic dose of paclitaxel, an antiproliferative drug, to the target lesion.
The incidence of esophageal adenocarcinoma has increased 8-fold over the past 50 years. This is one of the deadliest cancers, with a five-year survival rate of only 20 percent. However, the survival rate more than doubles if the cancer is identified early.
An international Yale-led research team has shown that a risk profile based on 52 genes accurately predicts survival for patients with a severe lung disease. If confirmed in further studies, the finding could transform the way patients are treated for the condition, which is on the rise in older adults.
The nation's emergency physicians are issuing a strong warning to parents about the dangers of prescription drug abuse, which are now the second most abused drugs, after marijuana. Nearly three-quarters of a million people (741,425) needed emergency care in 2006 because of prescription drug abuse.
› Verified 4 days ago
| Entity Name | Pm Healthcare, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1235670670 PECOS PAC ID: 9133496862 Enrollment ID: O20170530001313 |
News Archive
Cook Medical has submitted its Pre-Market Approval (PMA) application to the U.S. Food and Drug Administration (FDA) for the company's unique polymer-free Zilver® PTX® Drug-Eluting Peripheral Stent. Intended for use in patients with peripheral arterial disease (PAD) in the superficial femoral artery (SFA), Zilver PTX is a self-expanding, highly durable nitinol stent that uses a proprietary, polymer-free technology to deliver a locally therapeutic dose of paclitaxel, an antiproliferative drug, to the target lesion.
The incidence of esophageal adenocarcinoma has increased 8-fold over the past 50 years. This is one of the deadliest cancers, with a five-year survival rate of only 20 percent. However, the survival rate more than doubles if the cancer is identified early.
An international Yale-led research team has shown that a risk profile based on 52 genes accurately predicts survival for patients with a severe lung disease. If confirmed in further studies, the finding could transform the way patients are treated for the condition, which is on the rise in older adults.
The nation's emergency physicians are issuing a strong warning to parents about the dangers of prescription drug abuse, which are now the second most abused drugs, after marijuana. Nearly three-quarters of a million people (741,425) needed emergency care in 2006 because of prescription drug abuse.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Seth Garrett, MD 701 Leighton Ave, Anniston, AL 36207-5745 Ph: (256) 231-1231 | Seth Garrett, MD 701 Leighton Ave, Anniston, AL 36207-5745 Ph: (256) 231-1231 |
News Archive
Cook Medical has submitted its Pre-Market Approval (PMA) application to the U.S. Food and Drug Administration (FDA) for the company's unique polymer-free Zilver® PTX® Drug-Eluting Peripheral Stent. Intended for use in patients with peripheral arterial disease (PAD) in the superficial femoral artery (SFA), Zilver PTX is a self-expanding, highly durable nitinol stent that uses a proprietary, polymer-free technology to deliver a locally therapeutic dose of paclitaxel, an antiproliferative drug, to the target lesion.
The incidence of esophageal adenocarcinoma has increased 8-fold over the past 50 years. This is one of the deadliest cancers, with a five-year survival rate of only 20 percent. However, the survival rate more than doubles if the cancer is identified early.
An international Yale-led research team has shown that a risk profile based on 52 genes accurately predicts survival for patients with a severe lung disease. If confirmed in further studies, the finding could transform the way patients are treated for the condition, which is on the rise in older adults.
The nation's emergency physicians are issuing a strong warning to parents about the dangers of prescription drug abuse, which are now the second most abused drugs, after marijuana. Nearly three-quarters of a million people (741,425) needed emergency care in 2006 because of prescription drug abuse.
› Verified 4 days ago
Dr. Corey Gilliland, DO, MPH Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 731 Leighton Ave Ste 200, Anniston, AL 36207 Phone: 256-235-5972 Fax: 256-231-2583 | |
Robert Lamar Cater, MD,AAFP Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1425 Greenbrier Dear Rd, Anniston, AL 36207 Phone: 256-770-4327 Fax: 256-770-4309 | |
Donald Wayne Casey, D.O. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 700 Quintard Ave, Suite B, Anniston, AL 36201 Phone: 256-236-9400 Fax: 256-238-1498 | |
Michael Sesay, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 217 E 7th St, Anniston, AL 36207 Phone: 256-237-1535 Fax: 256-237-5053 | |
Dr. David A Chalk, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 400 E 8th St, Anniston, AL 36207 Phone: 256-237-8527 Fax: 256-237-0208 | |
Dr. Nadia Jonelle Mckitty, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 217 E 7th St, Anniston, AL 36207 Phone: 256-237-1535 |